Literature DB >> 12055205

Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators.

Benjamin L Hsu1, Susan M Harless, R Coleman Lindsley, David M Hilbert, Michael P Cancro.   

Abstract

These studies characterize BLyS responsiveness and receptor expression among transitional and mature peripheral B cells. The results show a maturation-associated increase in BLyS binding capacity that reflects differential expression patterns of the three BLyS receptors. Accordingly, BLyS administration enlarges only late transitional and mature peripheral B (MB) cell compartments. Furthermore, bromodeoxyuridine labeling and cell cycle analyses show these effects are mediated through enhanced proportional survival of cells traversing the T2, T3, and MB cell stages, rather than by causing proliferation or slowing transit within these subsets. Despite similar effects on survival, BLyS up-regulates the antiapoptotic genes A1 and bcl-x(L) in MB cells but not immature B cells. Together, these findings show that, while BLyS influences B cell survival in several peripheral differentiation subsets, the downstream mediators differ, thus providing the first direct evidence for an established B lineage survival system whose intermediates change as B cells mature.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055205     DOI: 10.4049/jimmunol.168.12.5993

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  107 in total

1.  Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments.

Authors:  Neda Nikbakht; Thi-Sau Migone; Chris P Ward; Tim Manser
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 2.  Peripheral B cell selection and homeostasis.

Authors:  Michael P Cancro; Susan Harless Smith
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses.

Authors:  Sreemanti Basu; Avijit Ray; Bonnie N Dittel
Journal:  J Immunol       Date:  2011-11-02       Impact factor: 5.422

Review 4.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

5.  Peripheral B cell tolerance and function in transgenic mice expressing an IgD superantigen.

Authors:  Bao Hoa Duong; Takayuki Ota; Djemel Aït-Azzouzene; Miyo Aoki-Ota; José Luis Vela; Christoph Huber; Kevin Walsh; Amanda L Gavin; David Nemazee
Journal:  J Immunol       Date:  2010-03-15       Impact factor: 5.422

6.  Early preplasma cells define a tolerance checkpoint for autoreactive B cells.

Authors:  Donna A Culton; Brian P O'Conner; Kara L Conway; Ramiro Diz; Jennifer Rutan; Barbara J Vilen; Stephen H Clarke
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

Review 7.  Effects of acute and chronic inflammation on B-cell development and differentiation.

Authors:  Derek Cain; Motonari Kondo; Huaiyong Chen; Garnett Kelsoe
Journal:  J Invest Dermatol       Date:  2009-02       Impact factor: 8.551

Review 8.  B cells and transplantation: an educational resource.

Authors:  Trudy N Small; William H Robinson; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 9.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

10.  Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; William J Quinn; Michael P Cancro; Huaxin Gao; Chaim Putterman; Xiaoni Gao; Luminita Pricop; Michael N Koss
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.